DIABETOLOGIA:从外显子广泛的相关性研究的蛋白尿

2019-05-06 不详 网络

鉴别与蛋白尿相关的罕见编码变异可能为预防慢性肾病和终末期肾病开辟新的途径,而这两种疾病在糖尿病患者中非常普遍。迄今为止,关于鉴别蛋白尿遗传易感性变异的工作还很有限,且大多数研究集中在常见的变异上。

鉴别与蛋白尿相关的罕见编码变异可能为预防慢性肾病和终末期肾病开辟新的途径,而这两种疾病在糖尿病患者中非常普遍。迄今为止,关于鉴别蛋白尿遗传易感性变异的工作还很有限,且大多数研究集中在常见的变异上。

本研究进行了一项外显子范围的关联研究,以两阶段(发现和复制)方法识别编码变体。纳入了来自欧洲血统的33,985(15,872人患有糖尿病18,113人没有糖尿病)2605名格陵兰人的数据。

研究结果发现了一个罕见的(小等位基因频率():0.8%)错义(A1690V)变体CUBN (rs141640975,β= 0.27,p = 1.3×10−11)。每一个罕见的变异等位基因的存在都与6.4%的蛋白尿增加有关。罕见的CUBN变体产生影响,三倍相比,患有2型糖尿病与那些没有(pinteraction = 7.0×10−4,患有糖尿病的β= 0.69,非糖尿病β= 0.20)发现荟萃分析。基于罕见和常见变异的基因聚合测试在多次测试校正(pBonferroni < 2.7×10−6)后发现了另外三个与蛋白尿相关的基因(HES1CDC73GRM5)

目前的研究确定了一种罕见的编码变异。这些基因与肾脏和血管功能障碍有关。这些发现为白蛋白尿的遗传结构提供了新的见解,并强调了预防糖尿病相关肾病的靶基因和途径。

原始出处:

Tarunveer S. Ahluwalia, A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761102, encodeId=d87c1e611022c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 14 02:45:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639094, encodeId=898a1639094ba, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue May 07 05:45:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837679, encodeId=fc19183e6791d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Jun 06 06:45:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619054, encodeId=043016190540e, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 08 13:45:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1761102, encodeId=d87c1e611022c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 14 02:45:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639094, encodeId=898a1639094ba, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue May 07 05:45:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837679, encodeId=fc19183e6791d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Jun 06 06:45:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619054, encodeId=043016190540e, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 08 13:45:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1761102, encodeId=d87c1e611022c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 14 02:45:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639094, encodeId=898a1639094ba, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue May 07 05:45:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837679, encodeId=fc19183e6791d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Jun 06 06:45:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619054, encodeId=043016190540e, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 08 13:45:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1761102, encodeId=d87c1e611022c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 14 02:45:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639094, encodeId=898a1639094ba, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue May 07 05:45:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837679, encodeId=fc19183e6791d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Jun 06 06:45:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619054, encodeId=043016190540e, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 08 13:45:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]

相关资讯

J Rheumatol:西罗莫司治疗狼疮性肾炎的长期数据

初步证据表明,西罗莫司可作为不能耐受标准治疗或有恶性肿瘤病史LN患者的替代治疗,并具有可接受的长期安全性。

他的IgA肾病,我为什么坚持推荐用激素治疗?

一个34岁男性患者网上咨询:7年前发现蛋白尿和高血压,曾找过三个中医间断服用中药治疗及降压药治疗,病情无明显好转。几个月前发现血肌酐升高165μmol/L,尿蛋白定量2.6g/d,而在当地医院行肾穿活检,病理结果为IgA肾病,里氏4级。

糖尿病大量蛋白尿,为何还要用激素治疗?

一个47岁男性,6年前查体发现血糖升高而住院治疗,出院后间断服用降糖药,空腹血糖维持在7mmol/L上下,餐后2小时血糖维持在10mmol/L上下,血压基本正常。

一个尿毒症病人的警示:每一个症状都不是无缘无故产生的

一个46岁的大叔,半年前突发急性心梗做冠脉支架手术,术前肾功能就不正常、血肌酐高(具体数值不详),术后医生建议他看肾内科,但这个建议出院后就被他甩到脑后。

JCEM:美曲普汀对脂肪代谢障碍患者蛋白尿的影响

由此可见,GLD患者的蛋白尿明显高于PLD患者,其中使用美曲普汀治疗可改善。导致脂肪代谢障碍的蛋白尿和使用美曲普汀改善蛋白尿的机制尚不清楚。超滤在GLD与PLD中也更常见,但与美曲普汀无关。

Circulation:采用沙普替利/缬沙坦治疗慢性肾病,额外具有降血压和心肌标志物的作用

沙普替利/缬沙坦可降低射血分数降低的心力衰竭患者的心血管死亡风险,但其对中重度慢性肾病患者肾功能和心脏生物标志物的影响尚不明确。UK HARP-III期试验是一个随机化的双盲试验,招募了414位肾小球滤过率(GFR)在20-60mL/min/1.73m2的患者,受试患者被随机分至沙普替利/缬沙坦组(97/103mg 2/日)或厄贝沙坦组(300mg 1/日),各207位患者。主要结点:12个月时,